- Open Access
A novel mutation in C5L2 gene was associated with hyperlipidemia and retinitis pigmentosa in a Chinese family
Lipids in Health and Disease volume 13, Article number: 75 (2014)
The Erratum to this article has been published in Lipids in Health and Disease 2014 13:110
Previous studies indicated that hyperlipidemia was associated with retinitis pigmentosa (RP). We aimed to identify the mutations in the C5L2 gene which was reported to be associated with hyperlipidemia in a Chinese family with (RP).
The Proband from the family was screened for mutations in the C5L2 gene that was known to cause hyperlipidemia. Cosegregation analysis was performed in the available family members. Linkage analysis was performed for one missense mutation to calculate the likelihood of its pathogenicity. One hundred and fifty unrelated, healthy Chinese subjects were screened to exclude nonpathogenic polymorphisms.
By direct sequencing method, we identified a novel mutation (Thr196Asn) in C5L2 gene. In this family, each affected family members with RP showed a heterozygous mutation in the C5L2 gene. And all the carriers with heterozygous mutation have increased serum lipid levels in this family.
The present study has extended the mutation spectrum of C5L2, and Thr196Asn mutations in C5L2 were associated with RP and serum lipid levels.
Retinitis pigmentosa (RP) is a hereditary retinal degeneration of unknown etiology, resulting in progressive night blindness, loss of peripheral vision, abnormal retinal pigmentation and reduced electroretinographic response . Nonsyndromic RP is the most common inherited form of severe retinal degeneration, with a prevalence of approximately 1/4,000 RP cases worldwide . Nonsyndromic cases can be inherited as an autosomal-dominant (20%–25%), autosomal-recessive (15%–20%), X-linked recessive (10%–15%), or sporadic/simplex (30%) trait .
Although there are more than 55 genes have been reported to be associated with RP, the mechanism of RP remains unclear. The previous studies suggested that lipid metabolism was abnormal in patients with RP [3, 4]. And Fujita et al. reported an association between a missense coding region polymorphism Asn985Tyr in the retinitis pigmentosa 1 gene (RP1), a causal gene for RP, and plasma triglyceride (TG) levels in 332 adult Japanese . These evidences suggested that abnormal metabolism of lipids may be associated with the RP patients. C5L2 is a G protein-coupled receptor (GPCR) and was demonstrated to be a functional receptor of acylation-stimulating protein (ASP) [6–8]. ASP is also known as C3a des-Arg, a stimulator of TG synthesis [9–12] or glucose transport [13, 14]. Previous study suggested that genetic mutation of C5L2 was associated with hyperlipidemia [15, 16]. Therefore, we hypotheses that the mutation in C5L2 gene is associated with risk for RP.
In the present study, we aimed to identify novel mutations in C5L2 gene in a RP family and to analyze the relation between this mutation and RP.
Recruitment of subjects
All participants were identified at Southwest Eye Hospital, the General Hospital of Chinese People’s Liberation Army. The diagnosis of RP was based on the presence of night blindness, typical fundus findings (characteristic retinal pigmentation, vessel attenuation, and various degrees of retinal atrophy), the severe loss of peripheral visual field, and abnormal electroretinogram (ERG) findings (dramatic diminution in amplitudes or the complete absence of response). Figure 1(A) showed the fundus pictures of the right (R) and left eye (L) of the index patient. ERG testing showed non-recordable responses (Figure 1B). This study was approved by the Institutional Review Board of Southwest Hospital, the General Hospital of Chinese People’s Liberation Army and adhered to the tenets of the Declaration of Helsinki and the Guidance on Sample Collection of Human Genetic Diseases by the Ministry of Public Health of China.
For each patient, a full medical and family history was taken and an ophthalmological examination was performed. Each underwent a standard ophthalmic examination: best correct visual acuity according to Snellen charts, slit-lamp biomicroscopy, dilated indirect ophthalmoscopy, fundus photography if possible, and visual field tests (Octopus; Interzeag, Schlieren, Switzerland). Retinal structure was examined by using optical coherence tomography (OCT; Topcon, Tokyo, Japan). ERGs were performed (RetiPort ERG system; Roland Consult, Wiesbaden, Germany) using corneal “ERGjet” contact lens electrodes. The ERG protocol complied with the standards published by the International Society for Clinical Electrophysiology of Vision.
Serum concentrations of total cholesterol (TC), Triglycerides (TG), glucose, high-density lipoprotein cholesterol (HDL-C), Low-density lipoprotein cholesterol (LDL-C) were measured using standard methods.
Genomic DNA was extracted from the peripheral white blood cells. We used 2ml blood which collected in EDTA vacutainer tubes. Genomic DNA was isolated from the peripheral leukocytes by using a QIAamp DNA Blood Midi Kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. All 2 coding exons of the C5L2 gene were sequenced. Sequence information for use as a reference template was obtained from the Ensembl Genome Browser (Human, number ENSG00000134830). Sequencing primers were described by Zheng et al. [15, 16]. The sense primer was 5′AAGATGCCACTTCTA ACAACA3′ and the antisense primer was 5′GTTGAATGAAGGAAGGAATAA3′. The PCR procedure was described previously . Briefly, the polymerase chain reaction (PCR) was undertaken with 50 ng of genomic DNA in a 20 μL reaction containing 10 μL of Power Mix (Beijing Biotech, Beijing, China), 9.5 μL of distilled water, and 0.2 mM of each forward and reverse primer. A GeneAmp 9700 thermal cycler (Applied Biosystems, Foster City, CA, USA) was used for PCR amplification. An initial denaturation step at 95°C for 5 min, 40 cycles of 95°C for 30 s, 56°C for 30 s, and 72°C for 1 min was followed by a final extension step of 72°C for 10 min. A 1615-base pair (bp) product was amplified was purified using ExoSAP-IT (Amersham Biosciences) according to manufacturer’s instructions before it was used as a template for sequencing. Sequencing reactions were undertaken by BGI-Beijing (Beijing, China; http://www.genomics.cn).
Data were analyzed using SPSS software 13.0. Statistical significance was accepted at p < 0.05. Values were expressed as mean ± SD for serum concentrations of TC, TG, HDL-C and LDL-C. Student’s t-test was performed to compare serum lipids levels between mutation carriers and wild carriers.
Upon complete sequence analysis of the coding regions of C5L2, three mutations were detected in four (RP patients) out of 16 family members, including one novel missense mutation (Thr196Asn) and two previously reported missense mutation (Pro233Leu, and rs36046934). The missense mutation c.587C>A in exon 1 resulted in a substitution of asparagine for threonine at codon 196 (Thr196Asn). This novel mutation (Thr196Asn) has not been found in 150 unrelated healthy subjects.
The relation between novel mutation and RP
The relation between novel mutation and lipids level
In this family, we also found the carriers with 196Asn allele have higher levels of TG (2.9 ± 1.3 mmol/L) and LDL-C (5.1 ± 1.4) (p < 0.05). However, the subjects without 196Asn allele have lower levels of serum lipids (TG, 1.6 ± 0.4; LDL-C, 3.3 ± 1.1) (p < 0.05) (Figure 4).
In the present study, we identified a novel missense mutation (Thr196Asn) in a RP family, and found this variant affects the risk for RP and hypertriglyceridemia. This is the first study to identify a novel mutation and analyze the relation between this mutation and RP.
The foundation for human studies examining putative causative genes that may be involved in RP is based on a candidate gene approach. A few studies into the genetic polymorphisms of the C5L2 receptor located on chromosome 19q13 (the region identified to be associated with familial combined hyperlipidemia and the pre-diabetic state by genome-wide scan studies) have been completed [17, 18]. Familial combined hyperlipidemia is considered to be the most frequent lipoprotein disorder in RP [3–5]. Therefore, the C5L2 gene is thought to be a candidate gene for RP.
In the present study, we identified three missense mutations in a family with RP. The Pro233Leu mutation was found by Zheng et al. in coronary artery disease (CAD) patient. Zheng et al. found the Pro233Leu variant was associated with CAD and Type 2 diabetes. The other variant- rs36046934 have been recorded in the NCBI database (http://www.ncbi.nlm.nih.gov/SNP). Therefore, in the present study, we did not analyze the relation between these two variants and RP. As for the mutation Thr196Asn, we did not find in 150 unrelated healthy subjects, which indicated that this mutation is a rare variant. In this RP family, all these four patients with RP have this mutation and the other eight members without RP have not this mutation, which suggested that the Pro233Leu variant is a causative mutation for RP in this family.
In addition, we also found the Pro233Leu variant was associated with increased TG and LDL-C levels in this family. However, the mechanisms may link to the RP and abnormal lipid level resulting from the C5L2 mutation is unclear and is worth exploring in the future.
In conclusion, the C5L2 may be a causative gene for RP with hyperlipidemia.
Ling-hui Qu and Xin Jin co-first authors.
Berger W, Kloeckener-Gruissem B, Neidhardt J: The molecular basis of human retinal and vitreoretinal diseases. Prog Retin Eye Res. 2010, 29: 335-375.
Ferrari S, Di Iorio E, Barbaro V, Ponzin D, Sorrentino FS, Parmeggiani F: Retinitis pigmentosa: genes and disease mechanisms. Curr Genomics. 2011, 12: 238-249.
Holman RT, Bibus DM, Jeffrey GH, Smethurst P, Crofts JW: Abnormal plasma lipids of patients with retinitis pigmentosa. Lipids. 1994, 29: 61-65.
Newsome DA, Anderson RE, May JG, McKay TA, Maude M: Clinical and serum lipid findings in a large family with autosomal dominant retinitis pigmentosa. Ophthalmology. 1988, 95: 1691-1695.
Fujita Y, Ezura Y, Emi M, Ono S, Takada D, Takahashi K, Uemura K, Iino Y, Katayama Y, Bujo H, Saito Y: Hypertriglyceridemia associated with amino acid variation Asn985Tyr of the RP1 gene. J Hum Genet. 2003, 48: 305-308.
Cui W, Simaan M, Laporte S, Lodge R, Cianflone K: C5a- and ASP-mediated C5L2 activation, endocytosis and recycling are lost in S323I-C5L2 mutation. Mol Immunol. 2009, 46: 3086-3098.
MacLaren R, Kalant D, Cianflone K: The ASP receptor C5L2 is regulated by metabolic hormones associated with insulin resistance. Biochem Cell Biol. 2007, 85: 11-21.
Kalant D, MacLaren R, Cui W, Samanta R, Monk PN, Laporte SA, Cianflone K: C5L2 is a functional receptor for acylation stimulating protein. J Biol Chem. 2005, 280: 23936-23944.
Cui W, Lapointe M, Gauvreau D, Kalant D, Cianflone K: Recombinant C3adesArg/acylation stimulating protein (ASP) is highly bioactive: a critical evaluation of C5L2 binding and 3T3-L1 adipocyte activation. Mol Immunol. 2009, 46: 3207-3217.
Faraj M, Sniderman AD, Cianflone K: ASP enhances in situ lipoprotein lipase activity by increasing fatty acid trapping in adipocytes. J Lipid Res. 2004, 45: 657-666.
Xiang SQ, Cianflone K, Kalant D, Sniderman AD: Differential binding of triglyceride-rich lipoproteins to lipoprotein lipase. J Lipid Res. 1999, 40: 1655-1663.
Paglialunga S, Julien P, Tahiri Y, Cadelis F, Bergeron J, Gaudet D, Cianflone K: Lipoprotein lipase deficiency is associated with elevated acylation stimulating protein plasma levels. J Lipid Res. 2009, 50: 1109-1119.
Saleh J, Al-Khanbashi M, Al-Maarof M, Al-Lawati M, Rizvi SG, Cianflone K: Acylation-stimulating protein increases and correlates with increased progesterone levels during the luteal phase of the menstrual cycle. Eur J Endocrinol. 2009, 160: 301-307.
de Lind van Wijngaarden RF, Cianflone K, Gao Y, Leunissen RW, Hokken-Koelega AC: Cardiovascular and metabolic risk profile and acylation-stimulating protein levels in children with Prader-Willi syndrome and effects of growth hormone treatment. J Clin Endocrinol Metab. 2010, 95: 1758-1766.
Zheng YY, Xie X, Ma YT, Yang YN, Fu ZY, Li XM, Ma X, Chen BD, Liu F: A novel polymorphism (901G > a) of C5L2 gene is associated with coronary artery disease in Chinese Han and Uyghur population. Lipids Health Dis. 2013, 12: 139-
Zheng YY, Xie X, Ma YT, Yang YN, Fu ZY, Li XM, Ma X, Chen BD, Liu F: Relationship between a novel polymorphism of the C5L2 gene and coronary artery disease. PLoS One. 2011, 6: e20984-
Huerta-Vazquez A, Aguilar-Salinas C, Lusis AJ, Cantor RM, Canizales-Quinteros S, Lee JC, Mariana-Nuñez L, Riba-Ramirez RM, Jokiaho A, Tusie-Luna T, Pajukanta P: Familial combined hyperlipidemia in Mexicans: association with upstream transcription factor 1 and linkage on chromosome 16q24.1. Arterioscler Thromb Vasc Biol. 2005, 25: 1985-1991.
Aouizerat BE, Allayee H, Cantor RM, Davis RC, Lanning CD, Wen PZ, Dallinga-Thie GM, de Bruin TW, Rotter JI, Lusis AJ: A genome scan for familial combined hyperlipidemia reveals evidence of linkage with a locus on chromosome 11. Am J Hum Genet. 1999, 65: 397-412.
This study was supported by the National Natural Sciences Foundation of China (No.81172873) and the National Basic Research Program of China (No.2013CB967002).
The authors declared no competing interests exist.
LHQ and XJ carried out the molecular genetic studies and drafted the manuscript. QLH and LML carried out the genotyping. ZQY, HPX and SYL participated in the design of the study and performed the statistical analysis. All authors read and approved the final manuscript.
An erratum to this article can be found online at 10.1186/1476-511X-13-110.
An erratum to this article is available at http://dx.doi.org/10.1186/1476-511X-13-110.
About this article
Cite this article
Qu, L., Jin, X., Li, L. et al. A novel mutation in C5L2 gene was associated with hyperlipidemia and retinitis pigmentosa in a Chinese family. Lipids Health Dis 13, 75 (2014) doi:10.1186/1476-511X-13-75
- Retinitis pigmentosa